, Volume 3, Issue 1, pp 57–68

Advances in the treatment of anxiety: Targeting glutamate


DOI: 10.1016/j.nurx.2005.12.005

Cite this article as:
Simon, A.B. & Gorman, J.M. NeuroRX (2006) 3: 57. doi:10.1016/j.nurx.2005.12.005


Our current psychopharmacological treatments for anxiety disorders evince a number of shortcomings, including troublesome side effects and lack of primary effects. Whereas many new drugs have been developed in the past few decades, most are based on outmoded theories of the pathogenesis of these disorders (i.e., monoamine hypotheses), thus frustrating our ability to create more specific and effective interventions. Recently, however, the neurobiological literature has shown a convergence of findings focusing on the glutamatergic system in anxiety disorders, and the growth of pharmacological tools targeting these receptors has led to the development of novel treatments having anxiolytic effects in humans and animals alike. Additionally, as this system is showing promise as a final common pathway in the pathogenesis of anxiety disorders, we may be able to employ glutamate-specific neuroimaging techniques (e.g., N-acetyl-aspartate, GLX) to both guide treatment decisions and present reliable objective biomarkers for treatment efficacy.

Key Words

GlutamateanxietystresspsychopharmacologytreatmentNMDA antagonist
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2006

Authors and Affiliations

  1. 1.Mount Sinai School of Medicine, Department of PsychiatryLaboratory of Clinical PsychobiologyNew York